The JI Acurri Cytometers
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Francini, G.
Right arrow Articles by Correale, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Francini, G.
Right arrow Articles by Correale, P.
The Journal of Immunology, 2002, 169: 4840-4849.
Copyright © 2002 by The American Association of Immunologists

High-Affinity HLA-A(*)02.01 Peptides from Parathyroid Hormone-Related Protein Generate In Vitro and In Vivo Antitumor CTL Response Without Autoimmune Side Effects1

Guido Francini2,*, Antonio Scardino{dagger}, Kostas Kosmatopoulos{dagger}, François A. Lemonnier{dagger}, Giuseppe Campoccia{ddagger}, Marianna Sabatino*, Daniele Pozzessere*, Roberto Petrioli*, Luisa Lozzi§, Paolo Neri§, Giuseppe Fanetti{ddagger}, Maria Grazia Cusi§ and Pierpaolo Correale*

* Division of Medical Oncology, {dagger} Institut National de la Santé et de la Recherche Médicale Unité d’Immunité Cellulaire Antivirale, Institut Pasteur, Paris, France; and {ddagger} Blood Bank and § Department of Molecular Biology, Siena University School of Medicine, Siena, Italy

Parathyroid hormone-related protein (PTH-rP), a protein produced by prostate carcinoma and other epithelial cancers, is a key agent in the development of bone metastases. We investigated whether the protein follows the self-tolerance paradigm or can be used as a target Ag for anticancer immunotherapy by investigating the immunogenicity of two HLA-A(*)02.01-binding PTH-rP-derived peptides (PTR-2 and -4) with different affinity qualities. PTH-rP peptide-specific CTL lines were generated from the PBMC of two HLA-A(*)02.01+ healthy individuals, stimulated in vitro with PTH-rP peptide-loaded autologous dendritic cells and IL-2. The peptide-specific CTLs were able to kill PTH-rP+HLA-A(*)02.01+ breast and prostate carcinoma cell lines. The two peptides were also able to elicit a strong antitumor PTH-rP-specific CTL response in HLA-A(*)02.01 (HHD) transgenic mice. The vaccinated mice did not show any sign of side effects due to cell-mediated autoimmunity or toxicity. In this study we describe two immunogenic and toxic-free PTH-rP peptides as valid candidates for the design of peptide-based vaccination strategies against prostate cancer and bone metastases from the most common epithelial malignancies.




This article has been cited by other articles:


Home page
Cancer Res.Home page
J. Eguchi, M. Hatano, F. Nishimura, X. Zhu, J. E. Dusak, H. Sato, I. F. Pollack, W. J. Storkus, and H. Okada
Identification of Interleukin-13 Receptor {alpha}2 Peptide Analogues Capable of Inducing Improved Antiglioma CTL Responses
Cancer Res., June 1, 2006; 66(11): 5883 - 5891.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. Correale, M. G. Cusi, K. Y. Tsang, M. T. Del Vecchio, S. Marsili, M. L. Placa, C. Intrivici, A. Aquino, L. Micheli, C. Nencini, et al.
Chemo-Immunotherapy of Metastatic Colorectal Carcinoma With Gemcitabine Plus FOLFOX 4 Followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Interleukin-2 Induces Strong Immunologic and Antitumor Activity in Metastatic Colon Cancer Patients
J. Clin. Oncol., December 10, 2005; 23(35): 8950 - 8958.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
P. Correale, M. T. Del Vecchio, G. Di Genova, G. G. Savellini, M. La Placa, C. Terrosi, M. Vestri, R. Urso, F. Lemonnier, A. Aquino, et al.
5-Fluorouracil-Based Chemotherapy Enhances the Antitumor Activity of a Thymidylate Synthase-Directed Polyepitopic Peptide Vaccine
J Natl Cancer Inst, October 5, 2005; 97(19): 1437 - 1445.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Machlenkin, A. Paz, E. Bar Haim, O. Goldberger, E. Finkel, B. Tirosh, I. Volovitz, E. Vadai, G. Lugassy, S. Cytron, et al.
Human CTL Epitopes Prostatic Acid Phosphatase-3 and Six-Transmembrane Epithelial Antigen of Prostate-3 as Candidates for Prostate Cancer Immunotherapy
Cancer Res., July 15, 2005; 65(14): 6435 - 6442.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. Correale*, M. G. Cusi, M. T. Del Vecchio, A. Aquino, S. Prete, K. Y. Tsang, L. Micheli, C. Nencini, M. La Placa*, F. Montagnani*, et al.
Dendritic Cell-Mediated Cross-Presentation of Antigens Derived from Colon Carcinoma Cells Exposed to a Highly Cytotoxic Multidrug Regimen with Gemcitabine, Oxaliplatin, 5-Fluorouracil, and Leucovorin, Elicits a Powerful Human Antigen-Specific CTL Response with Antitumor Activity in Vitro
J. Immunol., July 15, 2005; 175(2): 820 - 828.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. A. Rodeberg, R. A. Nuss, S. F. Elsawa, and E. Celis
Recognition of Six-Transmembrane Epithelial Antigen of the Prostate-Expressing Tumor Cells by Peptide Antigen-Induced Cytotoxic T Lymphocytes
Clin. Cancer Res., June 15, 2005; 11(12): 4545 - 4552.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Kobayashi, T. Nagato, K. Oikawa, K. Sato, S. Kimura, N. Aoki, R. Omiya, M. Tateno, and E. Celis
Recognition of Prostate and Breast Tumor Cells by Helper T Lymphocytes Specific for a Prostate and Breast Tumor-Associated Antigen, TARP
Clin. Cancer Res., May 15, 2005; 11(10): 3869 - 3878.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
W. N. Haining, D. G. Anderson, S. R. Little, M. S. von Berwelt-Baildon, A. A. Cardoso, P. Alves, K. Kosmatopoulos, L. M. Nadler, R. Langer, and D. S. Kohane
pH-Triggered Microparticles for Peptide Vaccination
J. Immunol., August 15, 2004; 173(4): 2578 - 2585.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Lane, J. Leitch, X. Tan, J. Hadjati, J. L. Bramson, and Y. Wan
Vaccination-Induced Autoimmune Vitiligo Is a Consequence of Secondary Trauma to the Skin
Cancer Res., February 15, 2004; 64(4): 1509 - 1514.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2002 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2002 by The American Association of Immunologists, Inc. All rights reserved.